Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions

Annals of the Rheumatic Diseases

Volumn 71, Issue 7, 2012, Pages 1227-1234

  Mathian, Alexis ^a,b,c   Parizot, Christophe ^b   Dorgham, Karim ^a,c   Trad, Salim ^b,c   Arnaud, Laurent ^a,b,c   Larsen, Martin ^a,c   Miyara, Makoto ^a,b,c   Hié, Miguel ^b   Piette, Jean Charles ^b,c   Frances, Camille ^c   Yssel, Hans ^a   Amoura, Zahir ^a,b,c   Gorochov, Guy ^a,b,c  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REGULATORY T LYMPHOCYTE; SKIN; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION; UPREGULATION;

BIOLOGICAL MARKERS; CELLS, CULTURED; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-17; INTERLEUKINS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84862565756     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200709     Document Type: Article

References (45)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67. (Pubitemid 46348510)
2. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
3. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
4. Gustafsson R, Tötterman TH, Klareskog L, et al. Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann Rheum Dis 1990;49:40-5.
5. Fiocco U, Rosada M, Cozzi L, et al. Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis 1993;52:272-7. (Pubitemid 23103357)
6. Kalogerou A, Gelou E, Mountantonakis S, et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005;64:1233-5. (Pubitemid 41113366)
7. Roumm AD, Whiteside TL, Medsger TA Jr, et al. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53. (Pubitemid 14089474)
8. Meloni F, Solari N, Cavagna L, et al. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol 2009;27:765-72.
9. Atamas SP, Yurovsky VV, Wise R, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168-78. (Pubitemid 29268953)
10. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007;19:345-54. (Pubitemid 46523383)
11. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006;103:6659-64.
12. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110:2983-90. (Pubitemid 350006952)
13. Wang J, Ioan-Facsinay A, van der Voort EI, et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007;37:129-38. (Pubitemid 46128793)
14. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
15. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
16. Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-{beta}. J Immunol 2005;174:1446-55.
17. Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008;453:65-71. (Pubitemid 351630328)
18. Deleuran B, Abraham DJ. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007;3:682-3. (Pubitemid 350187010)
19. Klein S, Kretz CC, Ruland V, et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 2011;70:1475-81.
20. Radstake TR, van Bon L, Broen J, et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS ONE 2009;4:e5981.
21. Slobodin G, Ahmad MS, Rosner I, et al. Regulatory T cells (CD4(+)CD25(bright) FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010;261:77-80.
22. Giovannetti A, Rosato E, Renzi C, et al. Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol 2010;137:122-33.
23. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-63.
24. Murata M, Fujimoto M, Matsushita T, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008;50:240-2.
25. Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS ONE 2009;4:e5903.
26. Truchetet ME, Brembilla NC, Montanari E, et al. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011;13:R166.
27. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
28. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
29. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8. (Pubitemid 32493986)
30. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
31. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006;203:359-70. (Pubitemid 43290845)
32. Valmori D, Merlo A, Souleimanian NE, et al. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005;115:1953-62. (Pubitemid 40979735)
33. Papp G, Horvath IF, Barath S, et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 2011;40:205-10.
34. Fenoglio D, Battaglia F, Parodi A, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011;139:249-57.
35. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86. (Pubitemid 38032120)
36. Fu S, Zhang N, Yopp AC, et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant 2004;4:1614-27. (Pubitemid 39312295)
37. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008;9:650-7. (Pubitemid 351712635)
38. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-9. (Pubitemid 44498362)
39. Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol 2011;23:159-63.
40. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009;87:523-36.
41. Aden N, Shiwen X, Aden D, et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) 2008;47:1754-60.
42. Van Praet JT, Smith V, Haspeslagh M, et al. Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res Ther 2011;13:R35.
43. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10:864-71.
44. Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10:857-63.
45. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319-24. (Pubitemid 37271558)